Kailera advances oral GLP-1 strategy after positive obesity and diabetes Phase 3 trials
Kailera Therapeutics has reported positive Phase 3 results for oral GLP-1 candidate KAI-7535 in obesity and type 2 diabetes, although high gastrointestinal event rates remain a major commercial and clinical concern.